NCT05471700View on ClinicalTrials.gov

Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

Azacitidine

Subjects will receive Azacitidine 75 mg/m2 on days 1-7.Each course is 28 days long.

DRUG

Venetoclax

Subjects would receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. Each course is 28 days long.

Trial Locations (1)

510250

Nanfang Hospital of Southern Medical University, Guanzhou

All Listed Sponsors
lead

Zhujiang Hospital

OTHER